Fla., the bill would require MACs to reach a decision on new LCD requests and LCD reconsideration requests within one year.

During a third phase of the pilot, set to begin in the third quarter of 2027, the EMA will open the program to IVD makers and notified bodies.

The assay delivers a risk score that can help clinicians to tailor treatment intensity to a patient's risk of disease progression.

As part of the deal, certain EHE members will be able to book a phlebotomist from Getlabs to go to their home or office to collect a patient sample for testing at Labcorp.

NEW YORK — Cancer Check Labs said on Thursday that it has signed an agreement to offer its blood-based cancer screening test through Evexia Diagnostics' ordering platform. The test — called ...

The parties aim to incorporate iFast's rapid AST system in clinical settings and develop evidence to support broader adoption by the NHS and other UK healthcare organizations.

The test is covered for recurrence monitoring following treatment with curative intent in individuals with  muscle-invasive bladder cancer and will be available starting June 1.

The firm's Lumipulse G pTau 217 Plasma measures phosphorylated tau 217 to assess whether an individual has the amyloid brain pathology characteristic of Alzheimer's disease.

Labcorp said the deal will streamline test ordering and reduce the time and cost of establishing and maintaining IT interfaces between the firm and its health system customers.

Company executives said that the firm's recent purchases of Saga Diagnostics and PathAI will provide synergies throughout its oncology portfolio.

The firm said that volume-based procurement headwinds facing its diagnostics business in China created a perfect storm with previously announced restructuring plans.

The company said that Medicare administrative contractor Novitas is attempting to recoup $10.4 million based on a retrospective review of Resolve MDx claims.